Document is current

Article History

Received: 5 June 2024

Accepted: 29 July 2024

First Online: 6 August 2024

Declarations

:

: <i>Sandra Ihne-Schubert:</i> S. Ihne-Schubert received financial reimbursement for consulting, advisory board activities, speaker honoraries and/or travel support to attend scientific meetings by Akcea Therapeutics, Alnylam, Pfizer, Janssen-Cilag, and Takeda, and further research funding from Pfizer and Akcea Therapeutics. An internship was supported by ONLUS. She was a fellow of the local Clinician Scientist program of the IZKF Würzburg. <i>Caroline Morbach:</i> C. Morbach reports research cooperation with the University of Würzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, Germany; she is supported by the German Research Foundation (DFG) within the Comprehensive Research Center 1525 ‘Cardio-immune interfaces’ (453989101, project C5) and receives financial support from the Interdisciplinary Center for Clinical Research—IZKF Würzburg (advanced clinician-scientist program; AdvCSP 3). She further received advisory and speakers honoraria as well as travel grants from Tomtec, Alnylam, AKCEA, Pfizer, Boehringer Ingelheim, SOBI, AstraZeneca, NovoNordisk, Alexion, Janssen, and EBR Systems; principal investigator in trials sponsored by Alnylam, Bayer, NovoNordisk, and AstraZeneca. <i>Maximilian Steinhardt:</i> no conflicts of interest. <i>Vladimir Cejka:</i> no conflicts of interest. <i>Aikaterini Papagianni: Stefan Frantz: S</i>. Frantz received consultancy and lecture fees as well as travel expenses from AMGEN Europe, AstraZeneca, Bayer Vital, Boehringer Ingelheim, Bristol-Meyers Squibb GmbH, Daiichi Sankyo, MSD, Novartis, Pfizer, Sanofi, Servier, Vifor. <i>Hermann Einsele:</i> no conflicts of interest. <i>Thomas Wehler: </i>no conflicts of interest. <i>Martin Kortüm:</i> no conflicts of interest. <i>Claudia Sommer:</i> C. Sommer received speaker honoraria from Alnylam. <i>Stefan Störk:</i> S. Störk received research support from the German Federal Ministry of Education and Research (BMBF). He has received consultancy and lecture fees from Akcea, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, NovoNordisk, Pfizer. His department received case payments for study participation from Akcea Therapeutics, Alnylam, IONIS. <i>Torben Schubert:</i> no conflicts of interest. <i>Andreas Geier:</i> A. Geier served as a steering committee member or advisor for AbbVie, Alexion, Bayer, BMS, Eisai, Falk, Gilead, Heel, Intercept, Ipsen, Merz, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis and as speaker for AbbVie, Advanz, Alexion, BMS, Burgerstein, CSL Behring, Falk, Gilead, Intercept, Merz, MSD, Novartis, NovoNordisc, Roche. He received research support from Intercept and Falk (both NAFLD CSG), Novartis.